| Patents for A61K 31 - Medicinal preparations containing organic active ingredients (785,912) |
|---|
| 07/07/2011 | CA2786255A1 Formulations from natural products, turmeric, and aspirin |
| 07/07/2011 | CA2786211A1 Nutritional compositions comprising fruit flakes including docosahexaenoic acid |
| 07/07/2011 | CA2786169A1 Materials and methods for prevention and treatment of viral infections |
| 07/07/2011 | CA2786155A1 Diazoxide for use in the treatment of a central nervous system (cns) autoimmune demyelinating disease |
| 07/07/2011 | CA2786002A1 Tricyclic compounds for use as kinase inhibitors |
| 07/07/2011 | CA2785983A1 Sirna for inhibition of c-met expression and anticancer composition containing the same |
| 07/07/2011 | CA2785957A1 .alpha.4.beta.2 neuronal nicotinic acetylcholine receptor ligands |
| 07/07/2011 | CA2785926A1 Injectable formulations for parenteral administration |
| 07/07/2011 | CA2785923A1 Therapeutic compounds and related methods of use |
| 07/07/2011 | CA2785898A1 Metalloenzyme inhibitor compounds |
| 07/07/2011 | CA2785846A1 Amino acid conjugates of quetiapine, process for making and using the same |
| 07/07/2011 | CA2785832A1 Treatment of interferon regulatory factor 8 (irf8) related diseases by inhibition of natural antisense transcript to irf8 |
| 07/07/2011 | CA2785749A1 Certain triazolopyridines and triazolopyrazines, compositions thereof and methods of use therefor |
| 07/07/2011 | CA2785727A1 Treatment of insulin receptor substrate 2 (irs2) related diseases by inhibition of natural antisense transcript to irs2 and transcription factor e3 (tfe3) |
| 07/07/2011 | CA2785716A1 Substituted pyrrolo-aminopyrimidine compounds |
| 07/07/2011 | CA2785714A1 Anaplerotic therapy for alzheimer's disease and the aging brain |
| 07/07/2011 | CA2785679A1 1,3,4-oxadiazole-2-carboxamide compound |
| 07/07/2011 | CA2785652A1 System for treating target tissue within the eustachian tube |
| 07/07/2011 | CA2785642A1 Compositions including pyruvate for companion animals and methods of use thereof |
| 07/07/2011 | CA2785641A1 Compositions including pyruvate for companion animals and methods of use thereof |
| 07/07/2011 | CA2785639A1 Melt extruded nicotine thin strips |
| 07/07/2011 | CA2785627A1 Methods for enhancing natural killer cell proliferation and activity |
| 07/07/2011 | CA2785622A1 Taste masked dosage forms of bitter tasting anti-retroviral drugs |
| 07/07/2011 | CA2785618A1 Pyrimidine compounds as mtor and pi3k inhibitors |
| 07/07/2011 | CA2785536A1 Substituted imidazopyridinyl-aminopyridine compounds |
| 07/07/2011 | CA2785461A1 Compositions and methods for treating hepatitis b virus infection |
| 07/07/2011 | CA2785341A1 Pyrazine derivatives and their use in the treatment of neurological disorders |
| 07/07/2011 | CA2785237A1 Sulphated disaccharides for the treatment of neurodegenerative and/or neurovascular diseases |
| 07/07/2011 | CA2785035A1 Intermediate compounds and processes for the preparation of tapentadol and related compounds |
| 07/07/2011 | CA2784842A1 Dibenzoyl peroxide derivatives, preparation method thereof and cosmetic or dermatological compositions containing same |
| 07/07/2011 | CA2784799A1 Certain dipeptidyl peptidase inhibtors |
| 07/07/2011 | CA2784768A1 Tetrahydrotriazolopyridine compounds as selective mglu5 receptor potentiators useful for the treatment of schizophrenia |
| 07/07/2011 | CA2784553A1 Thieno [2,3-b] pyridinedione activators of ampk and therapeutic uses thereof |
| 07/07/2011 | CA2784365A1 Low toxicity topical active agent delivery system |
| 07/07/2011 | CA2784153A1 Novel (heterocycle/tetrahydropyridine)-(piperazinyl)-1-alcanone and (heterocycle/dihydropyrrolidine)-(piperazinyl)-1-alcanone derivatives, and use thereof as p75 inhibitors |
| 07/07/2011 | CA2784152A1 Novel (heterocycle/condensed piperidine)-(piperazinyl)-1-alcanone or (heterocycle/condensed pyrrolidine)-(piperazinyl)-1-alcanone derivatives, and use thereof as p75 inhibitors |
| 07/07/2011 | CA2783230A1 New secondary 8-hydroxyquinoline-7-carboxamide derivatives |
| 07/07/2011 | CA2783216A1 Secondary 8-hydroxyquinoline-7-carboxamide derivatives for use as antifungal agents |
| 07/07/2011 | CA2783213A1 New tertiary 8-hydroxyquinoline-7-carboxamide derivatives and uses thereof |
| 07/07/2011 | CA2782980A1 Hair growth and/or regrowth compositions |
| 07/06/2011 | EP2341348A1 Methods for detecting cross beta structure comprising proteins with crossbeta structure binding compounds. |
| 07/06/2011 | EP2341346A2 Methods of high-throughput screening for internalizing antibodies and metal-chelating liposomes |
| 07/06/2011 | EP2341143A1 OX2 receptor homolog |
| 07/06/2011 | EP2341142A2 HLA-A*1101-restricted WT1 peptide and pharmaceutical composition comprising same |
| 07/06/2011 | EP2341058A2 Oligonucleotide Analogues |
| 07/06/2011 | EP2341057A2 Oligonucleotide Analogues |
| 07/06/2011 | EP2341053A1 Cephalosporin having catechol group |
| 07/06/2011 | EP2341052A1 Ring-fused morpholine derivative having pi3k-inhibiting activity |
| 07/06/2011 | EP2341050A1 Cytotoxic agents containing novel potent taxanes and their therapeutic use |
| 07/06/2011 | EP2341049A1 5-substituted 1,1-dioxo-[1,2,5]thiazolidine-3-one derivatives as PTPASE 1B inhibitors |
| 07/06/2011 | EP2341048A1 Thiazolium salt compound and the use of treating the protein aging disease |
| 07/06/2011 | EP2341047A1 Cyclohexane derivative and pharmaceutical use thereof |
| 07/06/2011 | EP2341046A2 Process for the preparation of 7-ethyl-10-[4-(1-piperidino)-1-piperidino] carbonyloxy-camptothecin hydrochloride trihydrate |
| 07/06/2011 | EP2341045A1 [[3-(2-amino-1,2-dioxoethyl)-2-ethyl-1-(phenylmethyl)-11H-indol-4-yl]oxy]acetic acid (acyloxy)alkyl or ((alkoxycarbonyl)oxy)alkyl ester as SPLA2 inhibitor |
| 07/06/2011 | EP2341044A1 Cycloalkylamine derivative |
| 07/06/2011 | EP2340872A1 New pharmaceutical formulations useful in the treatment of insomnia |
| 07/06/2011 | EP2340856A1 Cosmetic or dermatologic formulation comprising a nutrient medium phase |
| 07/06/2011 | EP2340851A1 Diagnosis method and therapeutic method for cancer |
| 07/06/2011 | EP2340849A1 Anti-NGF antibodies for the treatment of various disorders |
| 07/06/2011 | EP2340845A2 Repeat sequences of the CA125 gene and their use for diagnostic and therapeutic interventions |
| 07/06/2011 | EP2340843A1 Methods and compositions to treat myocardial conditions |
| 07/06/2011 | EP2340842A1 Composition for prevention of influenza viral infection comprising tannic acid, air filter comprising the same and air cleaning device comprising the filter |
| 07/06/2011 | EP2340841A1 Osteogenesis promoter comprising [4-(methylthio)phenylthio]methanebisphosphonic acid or pharmaceutically acceptable salt thereof as active ingredient |
| 07/06/2011 | EP2340840A1 Pulse dose Vitamin D drug for the treatment of hyperproliferative skin diseases |
| 07/06/2011 | EP2340838A1 Compositions and Methods of Treatment of Cancer |
| 07/06/2011 | EP2340837A1 Combination treatment of cancer comprising EGFR/HER2 inhibitors |
| 07/06/2011 | EP2340836A1 Co-crystals comprising VX-950 and their pharmaceutical compositions |
| 07/06/2011 | EP2340835A1 Piperidine and piperazine derivatives |
| 07/06/2011 | EP2340834A1 Enhanced Solubility of Ziprasidone |
| 07/06/2011 | EP2340833A2 Controlled release oxycodone compositions |
| 07/06/2011 | EP2340832A1 Morphinan-6-one compounds for the treatment or prevention of neurodegenerative diseases |
| 07/06/2011 | EP2340831A1 HT0712 for the treatment of a cognitive deficit |
| 07/06/2011 | EP2340830A2 Hepatitis C Virus Inhibitors |
| 07/06/2011 | EP2340829A1 Novel antischistosomal agent |
| 07/06/2011 | EP2340828A1 Pharmaceutical combinations of an angiotensin receptor antagonist and an nep inhibitor |
| 07/06/2011 | EP2340827A2 Method and preparation preventing and/or treating neurodegenerative or neurological disorders using a drug combination |
| 07/06/2011 | EP2340826A2 Method and preparation preventing and/or treating neurodegenerative or neurological disorders |
| 07/06/2011 | EP2340825A2 Method and preparation preventing and/or treating neurodegenerative or neurological disorders using a neurotransmitter precursor |
| 07/06/2011 | EP2340824A2 Method and preparation for reducing the severity of ADHD and/or motor disorders |
| 07/06/2011 | EP2340823A1 Iron chelating agent, method for producing same, method for determining amount of iron ions and method for trapping iron ions |
| 07/06/2011 | EP2340822A1 Acylated 4-amidino and 4-guanidinobenzylamines for inhibiting plasma kallikreins |
| 07/06/2011 | EP2340821A1 Prophylactic/ameliorating agent for adult diseases comprising 5-aminolevulinic acid, derivative of 5-aminolevulinic acid, or salt of 5-aminolevulinic acid or the derivative of 5-aminolevulinic acid as active ingredient |
| 07/06/2011 | EP2340820A1 Moisture-activated granulation process |
| 07/06/2011 | EP2340819A1 Compositions comprising venlafaxine and celecoxib in the treatment of pain |
| 07/06/2011 | EP2340818A1 Co-crystals of venlafaxine and celecoxib |
| 07/06/2011 | EP2340814A2 A stable aspirin tablet and process of preparation thereof |
| 07/06/2011 | EP2340813A1 Solid dosage formulations of galantamine |
| 07/06/2011 | EP2340810A1 Aripiprazole injectable suspension |
| 07/06/2011 | EP2340808A1 Synergic combination of phenylpropanoids, such as verbascoside or teupolioside, and mesalamine |
| 07/06/2011 | EP2340724A2 Treatment of stressed patients |
| 07/06/2011 | EP2340310A2 Reduced size self-delivering rnai compounds |
| 07/06/2011 | EP2340309A2 Neutral nanotransporters |
| 07/06/2011 | EP2340308A1 Combination of a chemotherapeutic agent and an inhibitor of the tgf-beta system |
| 07/06/2011 | EP2340307A2 Double-stranded ribonucleic acids with rugged physico-chemical structure and highly specific biologic activity |
| 07/06/2011 | EP2340257A1 Bidesmosidic betulin and betulinic acid derivatives and uses thereof as antitumor agents |
| 07/06/2011 | EP2340254A1 Compositions and methods for treating epilepsy |
| 07/06/2011 | EP2340251A1 Pyrrolo[4,3,2-de]quinolin-8-amine compounds and methods of their preparation and use |
| 07/06/2011 | EP2340250A1 Selective glycosidase inhibitors and uses thereof |
| 07/06/2011 | EP2340249A1 Poly-heteroaryl derivatives for the treatment of cancer |
| 07/06/2011 | EP2340248A2 Methods and compositions for modulating ire1, src, and abl activity |